Efficiency of Asiaticoside as Intracanal Medication in Revascularization Process
Efficiency of Asiaticoside as Intracanal Medication in Revascularization Process : Randomized Clinical Trial
- Immature Permanent Teeth With Open Apex
- Pulp Necrosis
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Mansoura University
- Enrolment target
- 20
- Started
- 1 October 2026
- Main results due
- February 2027
- Study sites
- 1
- Registry updated
- 23 September 2026
Can you take part?
- Ages 8 years to 18 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Both gender * patients having permanent anterior teeth with necrotic pulp and immature apex * Good general health * pulp space not needed for post and core Exclusion Criteria: * Radiographic identification of root fracture or abnormality * Uncooperative patients * Root resorption (internal or external)
What this study is about
In the sponsor’s own words, from the registry.
This study assess the ability of Asiaticoside based Intracanal medication compared to the commonly used Intracanal medicament ( calcium hydroxide Ca(OH) 2) on the outcome of the revascularization process in immature permanent teeth with pulp necrosis
Study sites(1)
Mansoura University
Al Mansurah, Egypt
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07802340. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me